Trends in antihypertensive drug advertising, 1985-1996

Thomas J. Wang, John C. Ausiello, Randall S. Stafford

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations

Abstract

Background - Over the past decade, calcium channel blockers (CCBs) and ACE inhibitors have been used increasingly in the treatment of hypertension. In contrast, β-blocker and diuretic use has decreased. It has been suggested that pharmaceutical marketing has influenced these prescribing patterns. No objective analysis of advertising for antihypertensive therapies exists, however. Methods and Results - We reviewed the January, April, July, and October issues of the New England Journal of Medicine from 1985 to 1996 (210 issues). The intensity of drug promotion was measured as the proportion of advertising pages used to promote a given medication. Statistical analyses used the X2 test for trend. Advertising for CCBs increased from 4.6% of advertising pages in 1985 to 26.9% in 1996, while advertising for β-blockers (12.4% in 1985 to 0% in 1996) and diuretics (4.2% to 0%) decreased (all P<0.0001). A nonsignificant increase was observed in advertising for ACE inhibitors (3.5% to 4.3%, P=0.17). Although the total number of drug advertising pages per issue decreased from 60 pages in 1985 to 42 pages in 1996 (P<0.001), the number of pages devoted to calcium channel blocker advertisements nearly quadrupled. Conclusions - Increasing promotion of CCBs has mirrored trends in physician prescribing. An association between advertising and prescribing patterns could explain why CCBs have supplanted better-substantiated therapies for hypertension.

Original languageEnglish (US)
Pages (from-to)2055-2057
Number of pages3
JournalCirculation
Volume99
Issue number15
DOIs
StatePublished - Apr 20 1999

Keywords

  • Advertising
  • Drug therapy
  • Hypertension
  • Practice patterns

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Trends in antihypertensive drug advertising, 1985-1996'. Together they form a unique fingerprint.

Cite this